KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Non-Current Liabilities: 2010-2024

Historic Other Non-Current Liabilities for Nektar Therapeutics (NKTR) over the last 15 years, with Dec 2024 value amounting to $7.2 million.

  • Nektar Therapeutics' Other Non-Current Liabilities fell 27.30% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 27.30%. This contributed to the annual value of $7.2 million for FY2024, which is 56.22% up from last year.
  • Per Nektar Therapeutics' latest filing, its Other Non-Current Liabilities stood at $7.2 million for FY2024, which was up 56.22% from $4.6 million recorded in FY2023.
  • Nektar Therapeutics' 5-year Other Non-Current Liabilities high stood at $27.7 million for FY2021, and its period low was $4.6 million during FY2023.
  • In the last 3 years, Nektar Therapeutics' Other Non-Current Liabilities had a median value of $7.2 million in 2024 and averaged $6.5 million.
  • In the last 5 years, Nektar Therapeutics' Other Non-Current Liabilities surged by 1,069.27% in 2020 and then plummeted by 72.77% in 2022.
  • Over the past 5 years, Nektar Therapeutics' Other Non-Current Liabilities (Yearly) stood at $9.0 million in 2020, then soared by 208.75% to $27.7 million in 2021, then slumped by 72.77% to $7.6 million in 2022, then crashed by 38.62% to $4.6 million in 2023, then spiked by 56.22% to $7.2 million in 2024.